Form 8-K ANAPTYSBIO, INC For: Jun 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Stifel Reiterates Buy Rating on AnaptysBio (ANAB)
June 4, 2025 7:15 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $55.00 price target on AnaptysBio (NASDAQ: ANAB).
The analyst comments "ANAB reported full 28wk results from the Rosnilimab Ph2b Rheumatoid Arthritis (RA) study. Rosnilimab continues to look highlyactive with efficacy competitive... More



